Toggle light / dark theme

New toothpaste stops periodontal pathogens

Periodontitis is widespread and can have serious consequences for overall health. Researchers at Fraunhofer have identified a substance that selectively inhibits only those bacteria that cause periodontitis, thereby preserving the natural balance of the oral microbiome. This technology has been further developed and commercialized as a range of oral care products by the spin-off company PerioTrap.

The oral microbiome is home to more than 700 different bacterial species, of which only a few can cause periodontitis. These adhere to dental plaque, particularly along the gum line, where they trigger inflammation (gingivitis). This can potentially lead to chronic periodontitis, which does more than just cause receding gums and loose teeth. If these bacteria enter the bloodstream, they can also contribute to the development of diabetes, rheumatic disease, arthritis, cardiovascular disease, chronic inflammatory bowel disease and even Alzheimer’s disease.

Pathogenic bacteria are killed by conventional oral care products such as alcohol-based mouthwashes and products containing the antiseptic chlorhexidine, but these also eliminate beneficial microorganisms. When the oral microbiome re-establishes itself after treatment, pathogenic bacteria such as Porphyromonas gingivalis gain an early advantage because they proliferate particularly well in inflamed gum tissue. Beneficial bacteria grow more slowly, and the oral microbiome quickly shifts back from its natural balance into dysbiosis, allowing the disease to recur.

Stem cell engineering breakthrough paves way for next-generation living drugs

For the first time, researchers at UBC have demonstrated how to reliably produce an important type of human immune cell — known as helper T cells — from stem cells in a controlled laboratory setting. The findings, published today in Cell Stem Cell, overcome a major hurdle that has limited the development, affordability and large-scale manufacturing of cell therapies. The discovery could pave the way for more accessible and effective off-the-shelf treatments for a wide range of conditions like cancer, infectious diseases, autoimmune disorders and more.

“This is a major step forward in our ability to develop scalable and affordable immune cell therapies.”

Dr. Peter Zandstra


Ranked among the world’s top medical schools with the fifth-largest MD enrollment in North America, the UBC Faculty of Medicine is a leader in both the science and the practice of medicine. Across British Columbia, more than 12,000 faculty and staff are training the next generation of doctors and health care professionals, making remarkable discoveries, and helping to create the pathways to better health for our communities at home and around the world.

Teens Spend Most School Phone Time on Social Media

“This moves the conversation beyond anecdotes and self-reports to real-world behavior,” said Dr. Jason Nagata.


How much time during school hours do teens spend on social media? This is what a recent study published in JAMA hopes to address as a team of researchers investigated connections between adolescent phone use during school. This study has the potential to help researchers, academic administrators, students, and parents become aware of the connections between adolescent phone use and all-around health.

For the study, the researchers analyzed data regarding smartphone app usage during school hours from 640 adolescents aged 13–18 through software installed on their phones that was approved by all participants and their parents. The goal of the study was to ascertain phone app usage during school hours, with data being obtained from September 2022 to May 2024. In the end, the researchers found that teens spent about 1.16 hours each school day on smartphones, mostly using social media apps, with higher use among older students and those from underprivileged households.

Dr. Christie M. Ballantyne & Dr. Alexander Tal — Oral PCSK9 Therapy And The Future Of Heart Disease

Oral PCSK9 Therapy And The Future Of Heart Disease — Dr. Christie Ballantyne MD, Director, Center for Cardiometabolic Disease Prevention, Baylor College of Medicine & Dr. Alexander Tal, MD.


Dr. Christie M. Ballantyne, MD is a Cardiologist and is one of the nation’s foremost experts on lipids, atherosclerosis and heart disease prevention. He holds many leadership positions at Baylor College of Medicine (https://www.bcm.edu/people-search/chr… including director of the Center for Cardiometabolic Disease Prevention, co-director of the Lipid Metabolism and Atherosclerosis Clinic, and chief of the Section of Cardiology.

With over 1,000 publications in the area of atherosclerosis, lipids, and inflammation, Dr. Ballantyne’s research on heart disease prevention has led him to become an established investigator for the American Heart Association and the recipient of continuous funding from the National Institutes of Health with a core focus on in basic research of leukocyte–endothelial interactions, translational research in biomarkers, and clinical trials.

Dr. Ballantyne’s many accomplishments have included being elected as Fellow of the American Association for the Advancement of Science, the American Society of Clinical Investigation, and the Association of American Physicians. In 2012, he received the American College of Cardiology Distinguished Scientist Award (Basic Domain).

In 2014 and 2015, Thomson Reuters recognized Dr. Ballantyne as one of “The World’s Most Influential Scientific Minds.” Clarivate Analytics, Web of Science, named Dr. Ballantyne as a “Highly Cited Researcher” 2017–2022 in the top 1% of researchers most cited.

How neuron groups team up to embed memories in context

Humans have the remarkable ability to remember the same person or object in completely different situations. We can easily distinguish between dinner with a friend and a business meeting with the same friend. “We already know that deep in the memory centers of the brain, specific cells, called concept neurons, respond to this friend, regardless of the environment in which he appears,” says Prof. Florian Mormann from the Clinic for Epileptology at the UKB, who is also a member of the Transdisciplinary Research Area (TRA) Life & Health at the University of Bonn.

However, the brain must be able to combine this content with the context in order to form a useful memory. In rodents, individual neurons often mix these two pieces of information. “We asked ourselves: Does the human brain function fundamentally differently here? Does it map content and context separately to enable a more flexible memory? And how do these separate pieces of information connect when we need to remember specific content according to context?” says Dr. Marcel Bausch, working group leader at the Department of Epileptology and member of TRA Life & Health at the University of Bonn.

Pain-sensing neurons kick-start immune responses that drive allergies and asthma

Pain-sensing neurons in the gut kindle inflammatory immune responses that cause allergies and asthma, according to a new study by Weill Cornell Medicine. The findings, published in Nature, suggest that current drugs may not be as effective because they only address the immune component of these conditions, overlooking the contribution of neurons.

“Today’s blockbuster biologics are sometimes only 50% effective and when the treatments do work, they sometimes lose their efficacy over time,” said senior author Dr. David Artis, director of the Jill Roberts Institute for Research in Inflammatory Bowel Disease and the Michael Kors Professor in Immunology at Weill Cornell.

While the idea may be new to the field, Dr. Artis has been thinking about the role the nervous system may play in allergies and asthma for about two decades. For example, many of the symptoms that characterize these conditions, like itching and wheezing, are known to be neuronally controlled. “That was one of the clues that prompted us to look closer for a connection,” Dr. Artis said.

New BMI uses AI to reveal hidden metabolic disorders

Researchers at Leipzig University and the University of Gothenburg have developed a novel approach to assessing an individual’s risk of metabolic diseases such as diabetes or fatty liver disease more precisely. Instead of relying solely on the widely used body mass index (BMI), the team developed an AI-based computational model using metabolic measurements. This so-called metabolic BMI shows that people of normal weight with a high metabolic BMI have up to a fivefold higher risk of metabolic disease. The findings have been published in the journal Nature Medicine.

The conventional body mass index, calculated using height and weight, may indicate overweight but does not reflect how healthy or unhealthy body fat actually is. According to BMI classifications, up to 30% of people are considered to be of normal weight but already show dangerous metabolic changes. Conversely, there are individuals with an elevated BMI whose metabolism remains largely unremarkable. This discrepancy can lead to at-risk patients being identified and treated too late.

For the current scientific study, the international research team analyzed data from two large Swedish population studies involving a total of almost 2,000 participants. In addition to standard health and lifestyle parameters, extensive laboratory data from blood samples and analyses of the gut microbiome were collected. Based on this dataset, the researchers developed a computational model that predicts metabolic BMI.

Boosting the cell’s own cleanup: New class of small molecules accelerate natural protein degradation

Cells have a remarkable housekeeping system: Proteins that are no longer needed, defective, or potentially harmful are labeled with a molecular “tag” and dismantled in the cellular recycling machinery. This process, known as the ubiquitin-proteasome system, is crucial for health and survival.

Now, an international team of scientists led by CeMM, AITHYRA and the Max Planck Institute of Molecular Physiology in Dortmund has identified a new class of small molecules that harness this natural system to accelerate the removal of an immune-modulating enzyme called IDO1.

The findings, published in Nature Chemistry, introduce a new concept in drug discovery that could transform how we target difficult proteins in cancer and beyond.

/* */